Novo Nordisk Quality Improvement and Patient Safety Survey
"It is increasingly important in the present era of health care reform that Emergency Medicine continues in efforts to improve quality and demonstrate the value we provide for our patients. Examining our practice to close quality gaps, optimize patient outcomes and reduce unnecessary variability are some of the ways we achieve this." – Richard Griffey, MD MPH, FACEP, Past Chair
Novo Nordisk was honored to sponsor the ACEP Quality Improvement and Patient Safety section luncheon at Scientific Assembly 13 in October. For that luncheon a survey was developed to better understand emergency physicians’ interest in quality improvement. The results will be used to build engaging educational and informative content for the emergency physician audience.
We would also appreciate your completion of the survey. <Please click here>
Novo Nordisk Inc. is a global health care company with 90 years of innovation and leadership rooted in the philosophy that the patient should be at the center of care. Additionally, our commitment to hemophilia builds on our 20 years of research and our promise to work with and listen to patients to improve treatment. As you may know, rare bleeding disorders like acquired hemophilia have the potential to impact hospital quality performance ratings.
Quality improvement and appropriate patient management are key components in helping minimize and prevent long-term issues that can contribute to higher costs in hemophilia and acquired hemophilia patients.
With new opportunities presented by national health care reform, hospitals stand to benefit from being pioneers in providing high-quality, coordinated care and avoiding readmissions.
Back to Newsletter